Genomic Health Inc.
) continues to demonstrate the clinical and economic merits of
its Oncotype DX breast cancer test. The company recently featured
positive data from 22 clinical studies at the St. Gallen
International Breast Cancer Conference.
ABAXIS INC (ABAX): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis
EDWARDS LIFESCI (EW): Free Stock Analysis
GENOMIC HEALTH (GHDX): Free Stock Analysis
To read this article on Zacks.com click here.
The latest data on Oncotype DX breast cancer test displayed its
ability to alter clinical decisions associated with individual
cancer treatment by drawing attention to critical questions.
Additionally, the test provides economic benefits to health care
systems on the back of accurate disease diagnosis and treatment
Findings from the decision impact data from France, Israel,
Spain, Germany, UK and the U.A.E. reassert that Oncotype DX
alters physician treatment recommendations. The inference from
these studies validate similar findings from 15 previously
reported Oncotype DX clinical utility studies from the U.S.,
Canada, Europe, Japan, Australia, Israel and Mexico.
Further, five health economic analyses from France, the
Netherlands, Ireland, Hungary and Mexico establish the cost
effectiveness of Oncotype DX ensuring considerable savings for
health care systems. According to results from the analyses
conducted in France, the use of Oncotype DX will prevent
unnecessary chemotherapy for patients and result in savings of €5
million. Additionally, Genomic Health demonstrated positive
findings from nine other studies.
The uncontested results from across the globe acknowledge the
proficiency of Oncotype DX test as the only genomic test proven
to predict chemotherapy benefit. The latest results further
enhance the efficacy of the company's lead product.
Peer reviewed validation data for Oncotype DX should help Genomic
Health gain foothold and reimbursement in new markets. Currently,
the company has established significant reimbursements in Canada,
Germany, UK, Ireland, Spain, Greece, Saudi Arabia and Israel. We
believe that higher global adoption of Oncotype DX should improve
overall growth for Genomic Health.
The stock carries a Zacks Rank #3 (Hold). While we remain on the
sidelines for Genomic Health, we believe that other medical
stocks such as
) warrant a look as each carry a Zacks Rank #2 (Buy).